Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31292 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Waiel Abusnina und 18 weiteren Autor:innen. Beteiligte Einrichtung: Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Absorbable Implants, Everolimus, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Financial support was provided by the Boston Scientific Corporation., Boston Scientific Corporation.
Abstract (Originalsprache)
Background
Long‐term clinical data on biodegradable‐polymer (BP) drug‐eluting stents (DES) are limited. The objective of this study was to assess the long‐term safety and efficacy of the BP‐DES SYNERGY compared to XIENCE V, a durable‐polymer (DP)‐DES.
Methods
We compared patients treated with BP‐DES or DP‐DES at our center from 2008 to 2020. The primary outcome was major adverse cardiac events (MACE), defined as the composite of all‐cause death, Q‐wave myocardial infarction (MI), and target vessel revascularization (TVR). Secondary endpoints were all‐cause death, Q‐wave MI, target lesion revascularization (TLR), and stent thrombosis (ST).
Results
A total of 4255 patients underwent propensity‐score matching, and 380 patients from each cohort were matched. There was no significant difference between BP‐DES and DP‐DES concerning MACE (5‐year estimates: 21.6% vs. 26.6%, log‐rank p = 0.259). Furthermore, there was no difference in the TLR rate (5‐year estimates: 7.3% vs. 8.6%, log‐rank p = 0.781). All‐cause death (5‐year estimates: 13.6% vs. 12.9%, log‐rank p = 0.72) and Q‐wave MI (5‐year estimates: 0.53% vs. 1.7%, log‐rank p = 0.427) were also comparable between the two groups. Of note, the rate of very late ST was very low and similar between the groups (5‐year estimates: 0.26% vs. 0.64%, log‐rank p = 0.698).
Conclusion
BP‐DES and DP‐DES demonstrate similar safety and efficacy at 5‐year follow‐up. Both can be used for the effective treatment of coronary artery disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia, USA.
ORCID-Profile: Lowell F Satler, Ron Waksman
Förderung
- Financial support was provided by the Boston Scientific Corporation.
- Boston Scientific Corporation
Zitieren
APA
Abusnina, W., Case, B. C., Zhang, C., Chitturi, K. R., Sawant, V., Chaturvedi, A., Haberman, D., Lupu, L., Sutton, J. A., Ali, S. W., Deksissa, T., Pokharel, S., Ozturk, S. T., Margulies, A., Ben-Dor, I., Hashim, H. D., Satler, L. F., Garcia-Garcia, H. M., & Waksman, R. (2025). Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31292
Vancouver
Abusnina W, Case BC, Zhang C, Chitturi KR, Sawant V, Chaturvedi A, et al. Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31292
BibTeX
@article{Abusnina2025,
author = {Abusnina, Waiel and Case, Brian C and Zhang, Cheng and Chitturi, Kalyan R and Sawant, Vaishnavi and Chaturvedi, Abhishek and Haberman, Dan and Lupu, Lior and Sutton, Jospeh A and Ali, Syed W and Deksissa, Teshome and Pokharel, Shreejana and Ozturk, Sevket T and Margulies, Adrian and Ben-Dor, Itsik and Hashim, Hayder D and Satler, Lowell F and Garcia-Garcia, Hector M and Waksman, Ron},
title = {Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31292}
}
EUVIMED